Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Scott and White Hospital & Clinic |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00397579 |
RATIONALE: Combinations of biological substances in DT388IL3 fusion protein may be able to carry cancer killing substances directly to the cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of DT388IL3 fusion protein and to see how well it works in treating patients with acute myeloid leukemia or myelodysplastic syndromes.
Condition | Intervention | Phase |
---|---|---|
Leukemia Myelodysplastic Syndromes |
Biological: DT(388)IL3 fusion protein Genetic: gene expression analysis Genetic: protein expression analysis Other: flow cytometry Other: immunoenzyme technique Other: laboratory biomarker analysis |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND# 11314): a Phase I/II Clinical Trial |
Estimated Enrollment: | 90 |
Study Start Date: | July 2006 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: This is a phase I, multicenter, dose-escalation study followed by a phase II, open-label study.
After completion of study treatment, patients are followed periodically for up to 5 years.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following:
Histologically or morphologically confirmed acute myeloid leukemia (AML), meeting 1 of the following criteria:
Relapsed or refractory AML after treatment with ≥ 1 prior conventional induction therapy
Poor-risk AML, as defined by any of the following criteria:
High-risk myelodysplastic syndromes diagnosed by morphologic, histochemical, or cell surface marker criteria
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
United States, North Carolina | |
Duke Comprehensive Cancer Center | Recruiting |
Durham, North Carolina, United States, 27710 | |
Contact: Clinical Trials Office - Duke Comprehensive Cancer Center 888-275-3853 | |
United States, Texas | |
M. D. Anderson Cancer Center at University of Texas | Recruiting |
Houston, Texas, United States, 77030-4009 | |
Contact: Clinical Trials Office - M. D. Anderson Cancer Center at the U 713-792-3245 | |
Scott and White Cancer Institute | Recruiting |
Temple, Texas, United States, 76502 | |
Contact: Arthur E. Frankel, MD 254-724-0094 | |
Canada, British Columbia | |
British Columbia Cancer Agency - Vancouver Cancer Centre | Recruiting |
Vancouver, British Columbia, Canada, V5Z 4E6 | |
Contact: Donna E. Hogge, MD 604-875-4863 |
Study Chair: | Arthur E. Frankel, MD | Scott and White Hospital & Clinic |
Responsible Party: | Scott and White Cancer Institute ( Arthur E. Frankel ) |
Study ID Numbers: | CDR0000511032, S-WHITE-22304, S-WHITE-050047 |
Study First Received: | November 8, 2006 |
Last Updated: | July 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00397579 History of Changes |
Health Authority: | Unspecified |
adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) recurrent adult acute myeloid leukemia |
secondary acute myeloid leukemia untreated adult acute myeloid leukemia de novo myelodysplastic syndromes previously treated myelodysplastic syndromes secondary myelodysplastic syndromes |
Precancerous Conditions Hematologic Diseases Myelodysplastic Syndromes Leukemia, Myeloid Leukemia, Myeloid, Acute Recurrence Leukemia |
Preleukemia Acute Myelocytic Leukemia Acute Myeloid Leukemia, Adult Neoplasm Metastasis Congenital Abnormalities Bone Marrow Diseases |
Neoplasms by Histologic Type Disease Precancerous Conditions Hematologic Diseases Myelodysplastic Syndromes Leukemia, Myeloid Leukemia, Myeloid, Acute |
Leukemia Preleukemia Neoplasms Pathologic Processes Syndrome Bone Marrow Diseases |